Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia - Full Text View

Sponsor:	Gynecologic Oncology Group
Collaborator:	National Cancer Institute (NCI)
Information provided by:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00081263

Purpose

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer or to treat early cancer. Celecoxib may be effective in preventing the development of cervical cancer in patients who have cervical intraepithelial neoplasia (CIN).

PURPOSE: This randomized phase II trial is studying how well celecoxib works in preventing cervical cancer in patients with CIN.

Condition	Intervention	Phase
Cervical Cancer Precancerous Condition	Drug: celecoxib Other: placebo	Phase II

Study Type:	Interventional
Study Design:	Allocation: Randomized Masking: Double-Blind Primary Purpose: Prevention
Official Title:	A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or CIN 3)

Resource links provided by NLM:

MedlinePlus related topics: Cancer Cervical Cancer

Drug Information available for: Celecoxib

U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:

Histologic complete response [ Designated as safety issue: No ]
Frequency and severity of adverse effects [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

HPV viral load, proliferation index, apoptosis index by TUNEL assay, angiogenesis (VEGF), and COX-2 in tissue, levels of VEGF and bFGF pre- and post-treatment in serum, and levels of celecoxib in serum following treatment [ Designated as safety issue: No ]

Estimated Enrollment:	130
Study Start Date:	June 2005

Arms	Assigned Interventions
Experimental: Arm I Patients receive oral celecoxib once daily for 14-18 weeks.	Drug: celecoxib Given orally
Placebo Comparator: Arm II Patients receive oral placebo once daily for 14-18 weeks.	Other: placebo Given orally

Detailed Description:

OBJECTIVES:

Primary

Determine the efficacy of celecoxib, in terms of achieving histologic complete or partial response, in patients with cervical intraepithelial neoplasia (CIN) 2/3 or 3.
Determine the toxicity of this drug in these patients.

Secondary

Determine the effect of this drug on changes in lesion size in these patients.
Determine the effect of this drug on human papillomavirus (HPV) viral load in these patients.
Correlate histologic response, HPV viral load, lesion size, proliferation index, apoptosis index, angiogenesis (VEGF) and COX-2 in tissue, amount of VEGF and bFGF in serum, and serum celecoxib levels during treatment in these patients.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to lesion size (covering ≤ ½ area of the cervix vs covering > ½ area of the cervix) and degree of cervical intraepithelial neoplasia (CIN) (CIN 2/3 vs CIN 3). Patients are randomized to 1 of 2 treatment arms.

Arm I: Patients receive oral celecoxib once daily for 14-18 weeks.
Arm II: Patients receive oral placebo once daily for 14-18 weeks. Patients undergo colposcopy at week 8 and between weeks 14 and 18. Between weeks 14 and 18, patients with evidence of disease also undergo large loop excision of the transformation zone (cone biopsy) or cervical biopsy and patients with no evidence of disease undergo a cervical biopsy to confirm the absence of disease on colposcopy.

PROJECTED ACCRUAL: A maximum of 130 patients (39 per treatment arm) will be accrued for this study within 13 months.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Histologically confirmed cervical intraepithelial neoplasia (CIN) 2/3 or 3 by cervical biopsy 2-8 weeks prior to study entry
- Pathology report must clearly state "CIN 2/3" or "3" OR "moderate-severe dysplasia," "moderate-severe dyskaryosis," "severe dysplasia," or "sever dyskaryosis."
  - No CIN 2 alone OR moderate dysplasia or dyskaryosis alone
Colposcopically visible cervical lesion at study entry that is consistent with biopsy
No evidence of endocervical dysplasia or invasive cancer by cytology or biopsy
No history of cervical cancer

PATIENT CHARACTERISTICS:

Age

18 and over

Performance status

GOG 0-2

Life expectancy

Not specified

Hematopoietic

Platelet count > 125,000/mm^3
Hemoglobin > 11.0 g/dL
WBC > 3,000/mm^3
No significant bleeding disorder

Hepatic

Bilirubin ≤ 1.5 times upper limit of normal (ULN) (> 1.5 times ULN allowed if due to Gilbert's disease)
AST and ALT < 2.0 times ULN
No hepatic disorder

Renal

Creatinine ≤ 1.5 times ULN
No known renal failure

Cardiovascular

No history of transient ischemic attack or stroke
No history of cardiovascular disease
No uncontrolled hypertension

Other

No undiagnosed abnormal vaginal bleeding
No known immunocompromised condition
No known allergic reaction (such as asthma, urticaria, or other reaction) to NSAIDs or aspirin
No known hypersensitivity to celecoxib
No known allergic reaction to sulfonamides
No history of peptic ulcer disease
Must be good candidate for delayed treatment of CIN (i.e., deemed reliable to return for follow-up and provide adequate contact information)
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy

Not specified

Chemotherapy

Not specified

Endocrine therapy

Not specified

Radiotherapy

Not specified

Surgery

No prior renal transplantation

Other

At least 15 days since prior nonsteriodal anti-inflammatory agents (NSAIDs) or aspirin
No other concurrent NSAIDs or aspirin
No concurrent fluconazole or lithium

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00081263

Locations

United States, Arkansas
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences	Recruiting
Little Rock, Arkansas, United States, 72205
Contact: Clinical Trial Office - Arkansas Cancer Research Center at Uni 501-686-8274
United States, Delaware
CCOP - Christiana Care Health Services	Recruiting
Newark, Delaware, United States, 19713
Contact: Clinical Trial Office - CCOP - Christiana Care Health Services 302-623-4450
United States, Indiana
Michiana Hematology-Oncology, PC - Elkhart	Recruiting
Elkhart, Indiana, United States, 46514
Contact: Michael W. Method, MD, MPH 574-237-1328
Elkhart General Hospital	Recruiting
Elkhart, Indiana, United States, 46515
Contact: Michael W. Method, MD, MPH 574-237-1328
Elkhart Clinic, LLC	Recruiting
Elkhart, Indiana, United States, 46514-2098
Contact: Michael W. Method, MD, MPH 574-237-1328
Howard Community Hospital	Recruiting
Kokomo, Indiana, United States, 46904
Contact: Michael W. Method, MD, MPH 574-237-1328
Center for Cancer Therapy at LaPorte Hospital and Health Services	Recruiting
La Porte, Indiana, United States, 46350
Contact: Michael W. Method, MD, MPH 574-237-1328
Michiana Hematology-Oncology, PC - South Bend	Recruiting
Mishawaka, Indiana, United States, 46545-1470
Contact: Michael W. Method, MD, MPH 574-237-1328
Saint Joseph Regional Medical Center	Recruiting
Mishawaka, Indiana, United States, 46545-1470
Contact: Michael W. Method, MD, MPH 574-237-1328
Michiana Hematology Oncology PC - Plymouth	Recruiting
Plymouth, Indiana, United States, 46563
Contact: Michael W. Method, MD, MPH 574-237-1328
CCOP - Northern Indiana CR Consortium	Recruiting
South Bend, Indiana, United States, 46601
Contact: Michael W. Method, MD, MPH 574-237-1328
Michiana Hematology Oncology PC - La Porte	Recruiting
Westville, Indiana, United States, 46391
Contact: Michael W. Method, MD, MPH 574-237-1328
United States, Michigan
Lakeside Cancer Specialists, PLLC	Recruiting
Saint Joseph, Michigan, United States, 49085
Contact: Michael W. Method, MD, MPH 574-237-1328
Lakeland Regional Cancer Care Center - St. Joseph	Recruiting
St. Joseph, Michigan, United States, 49085
Contact: Michael W. Method, MD, MPH 574-237-1328
United States, North Carolina
FirstHealth Moore Regional Community Hospital Comprehensive Cancer Center	Recruiting
Pinehurst, North Carolina, United States, 28374
Contact: Clinical Trials Office - FirstHealth Moore Regional Community 910-715-2200
United States, Ohio
Charles M. Barrett Cancer Center at University Hospital	Recruiting
Cincinnati, Ohio, United States, 45267
Contact: William E. Richards 806-796-1317
United States, Oklahoma
Oklahoma University Cancer Institute	Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Robert S. Mannel, MD 405-271-8787
Cancer Care Associates - Saint Francis Campus	Recruiting
Tulsa, Oklahoma, United States, 74136-1929
Contact: Robert S. Mannel, MD 405-271-8787
United States, South Dakota
Sanford Cancer Center at Sanford USD Medical Center	Recruiting
Sioux Falls, South Dakota, United States, 57117-5039
Contact: Clinical Trials Office - Sanford Cancer Center 605-328-1367
United States, Wisconsin
Medical College of Wisconsin Cancer Center	Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Clinical Trials Office - Medical College of Wisconsin Cancer C 414-805-4380

Sponsors and Collaborators

Gynecologic Oncology Group

National Cancer Institute (NCI)

Investigators

Study Chair:

Janet S. Rader, MD

Washington University Siteman Cancer Center

More Information

Additional Information:

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Philip J. DiSaia, Gynecologic Oncology Group
ClinicalTrials.gov Identifier:	NCT00081263 History of Changes
Other Study ID Numbers:	CDR0000360805, GOG-0207
Study First Received:	April 7, 2004
Last Updated:	January 27, 2012
Health Authority:	Unspecified

Keywords provided by National Cancer Institute (NCI):

cervical cancer
cervical intraepithelial neoplasia grade 2
cervical intraepithelial neoplasia grade 3

Additional relevant MeSH terms:

Neoplasms
Uterine Cervical Neoplasms
Disease
Precancerous Conditions
Cervical Intraepithelial Neoplasia
Carcinoma in Situ
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female
Pathologic Processes
Carcinoma

Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Celecoxib
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents

ClinicalTrials.gov processed this record on February 13, 2012